Press Releases May 13, 2026 09:00 AM

The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference

The Oncology Institute to Present at B. Riley Securities Institutional Investor Conference

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
TOI

The Oncology Institute, Inc., a leading value-based oncology group in the U.S., announced participation of its CEO and CFO at the upcoming B. Riley Securities Institutional Investor Conference. They will present and hold a fireside chat to discuss the company's operations and growth strategies, accessible via webcast.

The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference
TOI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The Oncology Institute is one of the largest value-based oncology providers in the U.S., serving approximately 1.9 million patients.
  • The company employs over 180 clinicians and operates more than 100 clinics across five states.
  • Senior executives to discuss company strategy and updates at a major investment conference, increasing investor engagement.

CERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the B. Riley Securities Institutional Investor Conference, being held in Marina Del Rey, CA on Thursday, May 21, 2026, including a fireside chat from 9:00–9:40 a.m. PT.

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

____________________________

About The Oncology Institute (www.theoncologyinstitute.com):

Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors
ICR Healthcare
TOI@icrhealthcare.com


Risks

  • The announcement is an investor presentation without new operational or financial disclosures, limiting immediate impact on financial performance.
  • Potential market uncertainty remains regarding the company’s future growth and profitability outside the presentation event.
  • Healthcare sector regulations and reimbursement changes could affect oncology care providers like The Oncology Institute.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026